173 related articles for article (PubMed ID: 32418314)
21. Serum mass profile signature as a biomarker of early lung cancer.
Widlak P; Pietrowska M; Polanska J; Marczyk M; Ros-Mazurczyk M; Dziadziuszko R; Jassem J; Rzyman W
Lung Cancer; 2016 Sep; 99():46-52. PubMed ID: 27565913
[TBL] [Abstract][Full Text] [Related]
22. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics.
López-Sánchez LM; Jurado-Gámez B; Feu-Collado N; Valverde A; Cañas A; Fernández-Rueda JL; Aranda E; Rodríguez-Ariza A
Am J Physiol Lung Cell Mol Physiol; 2017 Oct; 313(4):L664-L676. PubMed ID: 28619761
[TBL] [Abstract][Full Text] [Related]
23. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
Jin Y; Wang J; Ye X; Su Y; Yu G; Yang Q; Liu W; Yu W; Cai J; Chen X; Liang Y; Chen Y; Wong BH; Fu X; Sun H
Br J Cancer; 2016 Mar; 114(5):532-44. PubMed ID: 26908325
[TBL] [Abstract][Full Text] [Related]
24. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.
Indovina P; Marcelli E; Pentimalli F; Tanganelli P; Tarro G; Giordano A
Mass Spectrom Rev; 2013; 32(2):129-42. PubMed ID: 22829143
[TBL] [Abstract][Full Text] [Related]
25. Proteomic biomarkers for lung cancer progression.
Ren Y; Zhao S; Jiang D; Feng X; Zhang Y; Wei Z; Wang Z; Zhang W; Zhou QF; Li Y; Hou H; Xu Y; Zhou F
Biomark Med; 2018 Mar; 12(3):205-215. PubMed ID: 29424557
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers for Lung Cancer Screening and Detection.
Ostrin EJ; Sidransky D; Spira A; Hanash SM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2411-2415. PubMed ID: 33093160
[TBL] [Abstract][Full Text] [Related]
27. Identificationof potential lung cancer biomarkers by liquid chromatography tandem mass spectrometry-based proteomics analysis of secretomes of two lung cancer cell lines.
Shevchenko VE; Kovalev SV; Arnotskaya NE; Kudryavtsev IA
Eur J Mass Spectrom (Chichester); 2013; 19(5):377-89. PubMed ID: 24800421
[TBL] [Abstract][Full Text] [Related]
28. Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry.
Wu HY; Goan YG; Chang YH; Yang YF; Chang HJ; Cheng PN; Wu CC; Zgoda VG; Chen YJ; Liao PC
J Proteome Res; 2015 Aug; 14(8):3039-50. PubMed ID: 26120931
[TBL] [Abstract][Full Text] [Related]
29. Optomechanical devices for deep plasma cancer proteomics.
Kosaka PM; Calleja M; Tamayo J
Semin Cancer Biol; 2018 Oct; 52(Pt 1):26-38. PubMed ID: 28867489
[TBL] [Abstract][Full Text] [Related]
30. Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome.
Haince JF; Joubert P; Bach H; Ahmed Bux R; Tappia PS; Ramjiawan B
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163138
[TBL] [Abstract][Full Text] [Related]
31. Mass spectrometry-based proteomic profiling of lung cancer.
Ocak S; Chaurand P; Massion PP
Proc Am Thorac Soc; 2009 Apr; 6(2):159-70. PubMed ID: 19349484
[TBL] [Abstract][Full Text] [Related]
32. Proteomics biomarkers for non-small cell lung cancer.
Kisluk J; Ciborowski M; Niemira M; Kretowski A; Niklinski J
J Pharm Biomed Anal; 2014 Dec; 101():40-9. PubMed ID: 25175018
[TBL] [Abstract][Full Text] [Related]
33. Cancer biomarker discovery and translation: proteomics and beyond.
Hristova VA; Chan DW
Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
[TBL] [Abstract][Full Text] [Related]
34. Clinical proteomics in cancer: Where we are.
Panis C; Pizzatti L; Souza GF; Abdelhay E
Cancer Lett; 2016 Nov; 382(2):231-239. PubMed ID: 27561426
[TBL] [Abstract][Full Text] [Related]
35. [Omics technologies in diagnostics of lung adenocarcinoma].
Novikova SE; Kurbatov LK; Zavialova MG; Zgoda VG; Archakov AI
Biomed Khim; 2017 May; 63(3):181-210. PubMed ID: 28781253
[TBL] [Abstract][Full Text] [Related]
36. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
37. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.
Mazzone PJ; Sears CR; Arenberg DA; Gaga M; Gould MK; Massion PP; Nair VS; Powell CA; Silvestri GA; Vachani A; Wiener RS;
Am J Respir Crit Care Med; 2017 Oct; 196(7):e15-e29. PubMed ID: 28960111
[TBL] [Abstract][Full Text] [Related]
38. Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Nan Y; Du J; Ma L; Jiang H; Jin F; Yang S
Technol Cancer Res Treat; 2017 Feb; 16(1):66-74. PubMed ID: 26809240
[TBL] [Abstract][Full Text] [Related]
39. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
40. Potential molecular approaches for the early diagnosis of lung cancer (review).
Oak CH; Wilson D; Lee HJ; Lim HJ; Park EK
Mol Med Rep; 2012 Nov; 6(5):931-6. PubMed ID: 22923136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
